» Articles » PMID: 11115165

Risk of Developing a Subsequent Nonmelanoma Skin Cancer in Patients with a History of Nonmelanoma Skin Cancer: a Critical Review of the Literature and Meta-analysis

Overview
Journal Arch Dermatol
Specialty Dermatology
Date 2000 Dec 15
PMID 11115165
Citations 107
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess the risk of developing a basal cell carcinoma (BCC), and/or a squamous cell carcinoma (SCC), and/or Bowen disease (SCC in situ) after a nonmelanoma skin cancer (NMSC) of a specific type.

Data Sources: Four electronic databases were searched from January 1, 1966, to October 21, 1999.

Study Selection: We included all studies published in English, identified by standard search strategies, that provided original data quantifying the risk of an NMSC among persons with a previous NMSC.

Data Extraction: For each study and separate histological type of index skin tumor and subsequent skin tumor (SCC, BCC, NMSC, or Bowen disease), we determined the 3-year cumulative risk and the incidence rate of second tumors per 100 000 person-years. In cases where more than 1 study was assessing the risk of one specific tumor type after another, we undertook a formal meta-analysis. We compared the incidence of a subsequent SCC after an index SCC and of a subsequent BCC after an index BCC with the incidence of the first occurrence of such tumors in the comparable general population.

Data Synthesis: We identified and reviewed 17 studies that included data for 26 tumor combinations. Overall, the 3-year cumulative risk of a subsequent SCC after an index SCC is 18%, at least a 10-fold increase in incidence compared with the incidence of first tumors in a comparable general population. For BCCs, the 3-year cumulative risk is 44%, also at least a 10-fold increase in incidence compared with the rate in a comparable general population. The risk of developing a BCC in patients with a prior SCC is about equal to that risk among persons with a prior BCC, but the risk of developing an SCC in patients with a prior BCC is low (6%).

Conclusions: Although these studies vary in their study type, location, and biases, their results are consistent. The risk of developing a subsequent skin cancer of a specific type depends on the type of prior NMSC and number of prior skin tumors of that type. Based on these findings, follow-up strategies for patients with BCC and SCC are suggested.

Citing Articles

Head and neck cutaneous basal cell carcinoma: a retrospective analysis of tumour features, surgical margins and recurrences.

Di Maio P, Giudice M, Cavallero A, Carnevale C, Til-Perez G, Sarria-Echegaray P Eur Arch Otorhinolaryngol. 2025; .

PMID: 39979627 DOI: 10.1007/s00405-025-09216-z.


Recommendations for the management of cutaneous squamous cell carcinoma: a systematic multidisciplinary Delphi consensus approach.

Munoz Couselo E, Canueto J, Jerviz Guia V, Lopez Lopez A, Bermejo Segu J, Garcia Castano A Clin Transl Oncol. 2024; .

PMID: 39699741 DOI: 10.1007/s12094-024-03826-5.


Association of the expression of Bcl-2 and Ki-67 prognostic markers and apoptotic index with biological behaviour in aggressive and non-aggressive non-melanoma eyelid skin cancer.

Pridavkova Z, Plank L, Ziak P, Halicka J, Benca-Kapitanova K, Vida R Postepy Dermatol Alergol. 2024; 41(5):456-462.

PMID: 39606595 PMC: 11589630. DOI: 10.5114/ada.2024.144402.


Secondary cutaneous malignancy after treatment of basal cell carcinoma with hedgehog pathway inhibitor: a systematic review.

Pierce C, Wang R, Howe R, Burgess B, Owen J Arch Dermatol Res. 2024; 316(10):716.

PMID: 39460789 DOI: 10.1007/s00403-024-03471-6.


Epidemiology and Risk Factors of Actinic Keratosis. What is New for The Management for Sun-Damaged Skin.

Thamm J, Schuh S, Welzel J Dermatol Pract Concept. 2024; 14(3 S1).

PMID: 39133637 PMC: 11566825. DOI: 10.5826/dpc.1403S1a146S.